Clinical Trials Logo

Liver Inflammation clinical trials

View clinical trials related to Liver Inflammation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04389593 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference

Start date: May 21, 2019
Phase:
Study type: Observational

This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.

NCT ID: NCT03981211 Recruiting - Hepatitis C Clinical Trials

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

TOPIC
Start date: February 12, 2021
Phase: N/A
Study type: Interventional

This study will evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID (injecting related infectious diseases) and commencing inpatient DAA treatment within public hospital services.

NCT ID: NCT02931513 Recruiting - Clinical trials for Primary Biliary Cirrhosis

sCD163 in PBC Patients - Assessment of Treatment Response

Start date: September 2016
Phase:
Study type: Observational

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.